Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
International Journal of Cancer
|
May 31, 2012
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group
Sebastian Stintzing, Christine Kapaun, Rüdiger Paul Laubender, et al.
Clinical Colorectal Cancer
|
July 7, 2011
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer
Clemens Giessen, Sebastian Stintzing, Ruediger Paul Laubender, et al.
BMC Cancer
|
August 25, 2011
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 15, 2022
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314)
Dominik Paul Modest, Meinolf Karthaus, Stefan Kasper, et al.
Nature Medicine
|
October 18, 2025
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial
Alexander Stein, Eray Goekkurt, Salah-Eddin Al-Batran, et al.
Oncology Research and Treatment
|
April 2, 2024
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114)
Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2020
Amphiregulin Expression Is a Predictive Biomarker for <i>EGFR</i> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Arndt Stahler, Sebastian Stintzing, Dominik P Modest, et al.
Archives of Gynecology and Obstetrics
|
January 6, 2026
Between research and introduction to clinical routine-Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis)
Jacek P Grabowski, Julia Welz, Sabine Heublein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2011
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group
Nicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling-Kaiser, et al.
Frontiers in Oncology
|
November 1, 2023
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321)
Joseph Tintelnot, Alexander Stein, Salah-Eddin Al-Batran, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
International Journal of Cancer
|
May 31, 2012
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group
Sebastian Stintzing, Christine Kapaun, Rüdiger Paul Laubender, et al.
Clinical Colorectal Cancer
|
July 7, 2011
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer
Clemens Giessen, Sebastian Stintzing, Ruediger Paul Laubender, et al.
BMC Cancer
|
August 25, 2011
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 15, 2022
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314)
Dominik Paul Modest, Meinolf Karthaus, Stefan Kasper, et al.
Nature Medicine
|
October 18, 2025
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial
Alexander Stein, Eray Goekkurt, Salah-Eddin Al-Batran, et al.
Oncology Research and Treatment
|
April 2, 2024
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114)
Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2020
Amphiregulin Expression Is a Predictive Biomarker for <i>EGFR</i> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Arndt Stahler, Sebastian Stintzing, Dominik P Modest, et al.
Archives of Gynecology and Obstetrics
|
January 6, 2026
Between research and introduction to clinical routine-Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis)
Jacek P Grabowski, Julia Welz, Sabine Heublein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2011
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group
Nicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling-Kaiser, et al.
Frontiers in Oncology
|
November 1, 2023
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321)
Joseph Tintelnot, Alexander Stein, Salah-Eddin Al-Batran, et al.
Page
of 3